CXCR2 antagonists for the treatment of pulmonary disease

Chapman, R.W., Phillips, J.E., Hipkin, R.W., Curran, A.K., Lundell, D., Fine, J.S.·2009·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2008.10.005

Cites (205)

Items 201–205 of 205

  1. New endogenous CXC chemokine ligands as potential targets in lung emphysema
    Gert Folkerts, Aletta D. Kraneveld, Frans P. Nijkamp · 2008 · Trends in Pharmacological Sciences
  2. Chemokine Biology — Basic Research and Clinical Application
    Kuldeep S. Neote, Bernhard Moser, Gordon L. Letts · 2007 · Birkhäuser Basel eBooks
  3. Evaluation of Serum Interleukin-8 as a Marker of Disease Activity in Acute Asthma in Children
    Ren-Bin Tang, Shu‐Jen Chen · 2000 · Journal of Asthma
  4. Asthma and Chronic Obstructive Pulmonary Disease
    Gregory P. Roth, D.W. Green · 2007 · Elsevier eBooks
  5. N-Methyl-D-aspartate Attenuates CXCR2-Mediated Neuroprotection through Enhancing the Receptor Phosphorylation and Blocking the Receptor Recycling
    Qingwei Luo, Yun Ding, Kurt Watson, Jingwu Zhang, Guo-Huang Fan · 2005 · Molecular Pharmacology